CLSD-Top Gain: 101%- ( Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis)-Potential Short
Volumen 8.5M, Float 18.42M, Avg Vol (10 day) 3.07M, Avg Vol (3 month) 426.32k, NasdaqGM, Healthcare-Biotechnology, 1D Red Day
Entry 11.87, Stop Loss 12.15, Take Profit 10
Be ready if market make something unpredictable. Stay with your position, carefully!!!
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing TradingView Coins My Support Tickets Get Help Ideas Published Followers Following Private Messages Chat Sign Out